Jaime Rodriguez‐Canales
Papers
1
Total Citations
49
H-Index
1
About
Dr. Jaime Rodriguez‐Canales is a leading cancer biologist whose work bridges fundamental cell cycle mechanisms and therapeutic innovation. His research centers on the molecular vulnerabilities of lung cancer, particularly the role of cyclin-dependent kinases (CDKs) in driving tumor proliferation and the induction of anaphase catastrophe—a unique cell death pathway triggered by aberrant mitosis. His most cited work, a 2016 study (49 citations), investigates next-generation CDK2/9 inhibitors. In this landmark paper, Dr. Rodriguez‐Canales demonstrated that the potent inhibitor CCT68127 (Cyclacel) selectively kills lung cancer cells harboring supernumerary centrosomes by forcing multipolar anaphase and subsequent apoptosis. This contribution not only elucidated a novel mechanism of action—anaphase catastrophe—but also provided a compelling rationale for targeting CDK2/9 in tumors with centrosome amplification, a common feature of aggressive disease. By moving beyond first-generation agents like seliciclib, his work has directly informed the development of more selective, less toxic therapies. Dr. Rodriguez‐Canales’s research has thus had a significant impact on the field, shaping how we understand mitotic vulnerability and opening new avenues for precision oncology in lung cancer.
Research Focus
Key Achievements
Top Papers
- 1Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer49 citations · 2016